Over the last few years the way cancer research is conducted, funded, and clinically evaluated has been turned on its end.
The team model is also disrupting the normal course of business across the medical-research community. For investigators, it means changes in the way careers are developed, the way data — and especially credit for achievement — are shared. For institutions, team research means changes in contracts, compensation, titles and the path of intellectual property. For pharmaceutical companies, it means restructuring the way experimental drugs are allocated and clinical trials are conducted.
This sounds exactly like what we need for education.
Throw a lot of money at multi-disciplinary teams comprised of only those at the top of the field, review progress often, and expect result not papers and theories within a few years.